Hematology/Oncology Fellowship Program
At the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta, we offer three-year fellowships in collaboration with Emory University School of Medicine to qualified, promising physicians. We are dedicated to providing a comprehensive program for training subspecialty fellows in pediatric hematology/oncology.

**Our goal**

Our goal is to train academically oriented hematologists and oncologists who will be involved in a lifetime of excellence in patient care and teaching, in addition to clinical, translational or basic research. Upon successful completion of our training program, fellows will:

- Have a thorough understanding of the pathophysiology of pediatric hematologic and oncologic disorders.
- Be competent in the clinical diagnosis and management of these disorders.
- Understand clinical trials methodology.
- Have excellence in a selected research interest. Our program seeks to cultivate and encourage laboratory researchers and clinical investigators.

One of the largest pediatric hematology/oncology fellowship programs in the country

---

### Clinical rotations—first year

- Oncology ward service (three months)
- Blood and marrow transplant (BMT)—inpatient/outpatient service (two months)
- Hematology ward (two months)
- Outpatient hematology service (two months)
- Neuro-oncology—inpatient/outpatient service (one month)
- Lab rotation—radiation oncology, hematopathology, flow cytometry, cytogenetics, blood banking and special coagulation (one month total, divided into two-week blocks)
- Research exploration (one month total, divided into two-week blocks)

### Research—second and third year

Second- and third-year fellows are offered a variety of opportunities in clinical, translational and basic research. These opportunities are available at the Aflac Cancer Center and within specific divisions of the Emory University School of Medicine Department of Pediatrics.

We are devoted to training physician-scientists seeking careers in laboratory-based academic pediatric hematology/oncology. Research opportunities are performed in collaboration with faculty at the Winship Cancer Institute of Emory University, the Emory School of Public Health, the Yerkes National Primate Research Center and the Centers for Disease Control and Prevention (CDC).

In addition to the laboratory-based research track, we offer a clinical research track for fellows interested in careers as clinical investigators. Formal training in clinical research can be obtained through early involvement in several ongoing clinical trials within the institution. Fellows interested in clinical research are encouraged to apply for Emory’s Master of Science in Clinical Research (MSCR) program. We are in a unique position to offer special resources for laboratory and clinical training for the entire fellowship period and for extended periods of research time, if required.

We have an individualized scholarship oversight/mentoring committee for each fellow to guide him through his fellowship research experience.

### Research—optional fourth year

The fourth year is almost exclusively devoted to research and is available with funding to all fellows. This allows fellows to increase their skills for competitiveness in garnering future K-type or other awards for young investigators.

### On-call schedule

Night call takes place from home. Fellows occasionally return to the hospital to evaluate extremely ill or newly diagnosed patients:

- First year: 53 weekday nights and 12 weekends (one/month)
- Second year: 46 weekday nights and eight weekends
- Third year: Four weekday nights and six weekends
Didactic schedule

A variety of conferences and seminars are offered. A sample schedule is listed below. Additionally, structured teaching, ethics and research overview courses are offered throughout the year.

<table>
<thead>
<tr>
<th>Monday</th>
<th>Tuesday</th>
<th>Wednesday</th>
<th>Thursday</th>
<th>Friday</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.M.</td>
<td>Division</td>
<td>Core curriculum</td>
<td>Grand rounds</td>
<td>Patient care conference</td>
</tr>
<tr>
<td>P.M.</td>
<td>conference</td>
<td>review</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Tumor board | Research conference |

Additional benefits of the program

Fellows receive three weeks of vacation each year. Each fellow has an educational stipend that may be used for meetings, journals or other educational expenses. Senior fellows attend additional scientific meetings based on research presentations.

Accreditation

First accredited in the 1980s, the Fellowship Program received full accreditation by the Accreditation Council for Graduate Medical Education (ACGME) in 2004. The Aflac Cancer Center is affiliated with the Emory University School of Medicine, which is ranked among the top research medical schools in the country by U.S. News & World Report.

Funding

Fellows are fully funded throughout the three-year program. Additional years of research training, including application for the MSCR program, are available for qualified candidates.

Current fellows

First-year fellows

Ashley Eason, M.D.
ashley.eason@choa.org
College: University of Georgia
Medical School: Mercer University
Residency: University of Virginia
“When applying for a fellowship, I wanted to find a program that was strong in both hematology and oncology that also provided ample research opportunities. During my first few months, Emory has provided that and more with supportive faculty, engaging teaching sessions and broad clinical exposure.”

Dan Runco, M.D.
daniel.runco@choa.org
College: Creighton University
Medical School: Loyola University Chicago Stritch School of Medicine
Residency: Riley Hospital for Children, Indiana University
“Emory has the best of all worlds and this program pushes you to develop and pursue your own interests—not to fit into someone else’s mold. There are clinical and research opportunities in all aspects of hematology and oncology and I felt like if I trained here, there was no door that was closed to me.”

Jenny Shim, M.D.
jenny.shim@choa.org
College: Siena College
Medical School: Albany Medical College
Residency: University of Texas Southwestern Dallas
“What I love about Emory is its infinite potential to grow and the fact that it continues to grow both in patient care and research. We have a wonderful faculty group that provides well-rounded and personal mentorship. The research opportunities and career development with fourth year support in both hematology and oncology is invaluable.”

Sherri Smart, M.D. Ph.D.
sheri.smart@choa.org
College: University of Central Arkansas
Medical School: University of Arkansas
Residency: University of Cincinnati (Medicine-Pediatrics)
“Children’s is a strong academic center with equal focus in hematology and oncology and ample research opportunities in clinical, translational and basic science. During my interview, the biggest thing that stood out in my mind was how happy the fellows, faculty and staff were. I can tell you now that what you see on the surface holds true: We truly are a family.”

Michael White, M.D.
michael.white@choa.org
College: Harding University
Medical School: University of Texas Southwestern Medical School
Residency: Vanderbilt University
“I chose to train at Emory not only because they are one the largest and most robust hematology/oncology centers in the country, but because the people here are top-notch. The research and professional opportunities are endless here, and I could not feel more supported by our leadership. I’m thrilled to be in Atlanta.”

Monday Tuesday Wednesday Thursday Friday
A.M. Division conference | Core curriculum review | Grand rounds | Patient care conference
P.M. Tumor board | Research conference
Second-year fellows

Ashley Lanzel, M.D.
ashley.lanzel@choa.org
College: University of Georgia
Medical school: Medical College of Georgia
Residency: Johns Hopkins University

“Emory is a stand out program in my mind. It provides excellent clinical care to a large patient population with hematologic and oncologic maladies. The research possibilities are vast, from basic science, to clinical trials, to collaborations with other institutions, including Georgia Tech and the CDC. The opportunities are endless and the team is incredibly friendly, not to mention supportive.”

Lane Miller, M.D.
lane.miller@choa.org
College: Emory University
Medical school: Medical College of Georgia
Residency: Oregon Health & Science University

“The fellowship here at Emory was highly attractive to me for a number of reasons: the two-hospital system, the breadth of research options and mentors and the sheer exposure to such a wide variety of pathology amongst an equally diverse population. I should also mention how impressed I was and am with the collegial, friendly, humble, and brilliant personalities I have encountered here. This is truly a wonderful learning environment well established to allow fellows to thrive.”

Ryan Summers, M.D.
ryan.summers@choa.org
College: University of Georgia
Medical school: Emory University
Residency: Emory University

“We have a fantastic group of faculty who are invested in developing our careers as both clinicians and academicians. I love the diversity of the patient population and the equal strength in both hematology and oncology.”

Karen Zimowski, M.D.
karen.zimowski@choa.org
College: Clemson University
Medical school: Medical College of Georgia
Residency: Johns Hopkins University

“Emory’s Hematology/Oncology program is unique in that it is truly strong both in hematology and oncology. Atlanta has a large and diverse population and a busy service, which provides broad exposure to a multitude of disease processes and practice styles. While there are ample research opportunities within the department itself, Emory’s research connections spread beyond to places like the Winship Cancer Institute, Georgia Tech and the CDC. I am confident that I will end the fellowship well-trained and ready to start my career.”

Third-year fellows

Marcus Carden, M.D.
marcus.carden@choa.org
College: University of North Carolina
Medical school: Brody School of Medicine/East Carolina University
Residency: University of North Carolina at Chapel Hill

Current research: Utilizing bioengineering and nanotechnology to study the pathological basis of sickle cell disease

“I was attracted to the fellowship program because of its equal emphasis on providing excellent training for those interested in both hematology and oncology. The program’s two-hospital system is a unique benefit that exposes trainees to an array of common and uncommon hematological and oncological disorders with both common and uncommon presentations.”

Jim Felker, M.D.
james.felker@choa.org
College: Cornell University
Medical school: New York Medical College
Residency: Northwestern University/Lurie Children’s Hospital

Current research: Developing a brain tumor slice model for rapid drug testing and development

“I chose this program because it offered the greatest balance of a busy clinical program where I could learn about all facets of hematology/oncology through experiential learning, while having the resources and tools to help train me to be competitive in academic medicine.”

Sarah Mitchell, M.D.
sarah.mitchell2@choa.org
College: St. Olaf College
Medical school: Creighton University
Residency: University of Minnesota/Amplatz Children’s Hospital

Current research: Developing a 3-D, in vitro model of the medulloblastoma perivascular niche using an endothelialized microfluidic system with plan to investigate vascular niche factors involved in modulation of the cancer stem cell phenotype

“Everyone I have encountered at Emory and Children’s has been extremely friendly and helpful. We have an amazing group of nurse practitioners who are excellent teachers. The service is busy and has a very diverse patient population, providing exceptional training in all aspects of hematology/oncology.”

Patricia Zerra, M.D.
patricia.zerra@choa.org
College: Connecticut College
Medical school: Jefferson Medical College
Residency: University of Miami/Jackson Memorial

Current research: Understanding the role of CD4+ T cells and marginal zone B cells in the immune response against incompatible blood, and formation of inhibitors in hemophilia A

“I chose this program because it was a medium- to large-sized program, and I felt that it truly had a good mix of both hematology and oncology exposure that would help me decide what path I want to take. Most importantly, everyone was extremely inviting and friendly. I felt very comfortable on my interview day and knew it would be a good environment for me to learn.”
The two-campus model provides more depth to the fellows’ clinical experience. I feel that our learning is enhanced by exposure to the academic and private practice settings.”

—Jonathan Metts, M.D.
Dr. Graham is a National Institutes of Health-funded (NIH) investigator with an active laboratory focusing on developing novel therapeutics for pediatric cancer, recently validating MerTK as a novel cancer agent in leukemia, melanoma, non-small cell lung cancer and glioblastoma. He has served in multiple leadership roles with the American Society of Pediatric Hematology/Oncology and has an appointment as a full member of the NIH Molecular and Cellular Hematology Study Section.

- Lead the Biology and Treatment of Childhood Cancer Research Emphasis Area, where he directly oversees all basic science, translational and clinical oncology research.
- Served as the co-program leader of the Hematologic Malignancy Program at the University of Colorado, a National Cancer Institute-designated cancer center.

Dr. Graham was recently appointed as Director, Aflac Cancer Center. Dr. Graham previously served as professor of pediatrics and immunology at the University of Colorado, with clinical practice at Children's Hospital Colorado. While at Children's Hospital Colorado, Dr. Graham:

- Oversaw all basic science, translational and clinical oncology research.
- Led the Biology and Treatment of Childhood Cancer Research Emphasis Area, where he directly oversaw all basic science, translational and clinical oncology research.
- Served as the co-program leader of the Hematologic Malignancy Program at the University of Colorado, a National Cancer Institute-designated cancer center.

### Fellowship Program

**William Woods, M.D.**
- Director, Fellowship Program
- Professor and Director Emeritus
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta

**Glen Lew, M.D.**
- Associate Director, Fellowship Program
- Aflac Cancer and Blood Disorders Center
- Emory University School of Medicine

**Olufolake Adisa, M.D./M.S.C.R.**
- Associate Director, Fellowship Program
- Aflac Cancer and Blood Disorders Center
- Emory University School of Medicine

**Blood and marrow transplant (BMT)**

**Shanmuganathan Chandrakasan, M.D.:** Hematopoietic cell transplant/gene therapy for immune deficiency, immune deficiency, immune dysregulation and HLH, immunohematology and bone marrow failure, stem cell biology

**Ann E. Haight, M.D., Medical Director of BMT:** BMT in sickle cell disease and other nonmalignant diseases, supportive care in BMT and infections in the immunocompromised host, and clinical research ethics

### Leadership

**Division Director**
**Douglas K. Graham, M.D., Ph.D.**
- Professor and Director, Aflac Cancer and Blood Disorders Center
- Children's Healthcare of Atlanta

Douglas Graham, M.D., Ph.D. was recently appointed as Director, Aflac Cancer Center. Dr. Graham previously served as professor of pediatrics and immunology at the University of Colorado, with clinical practice at Children's Hospital Colorado. While at Children's Hospital Colorado, Dr. Graham:

- Lead the Biology and Treatment of Childhood Cancer Research Emphasis Area, where he directly oversees all basic science, translational and clinical oncology research.
- Served as the co-program leader of the Hematologic Malignancy Program at the University of Colorado, a National Cancer Institute-designated cancer center.

**Hematology**

**General hematology**

**Staci Arnold, M.D.:** Health outcomes, cost benefit analysis, comparative effectiveness research for sickle cell disease and bone marrow failure syndromes

**Jeanne M. Boudreaux, M.D., Clinical Director of Hematology:** Thalassemias, bone marrow failure syndromes, hemolytic anemias and white cell disorders

**Michael A. Briones, D.O.:** Vascular anomalies, histiocytic disorders, general hematology and inherited bone marrow failure syndrome

**Satheesh Chonat, M.D.:** Red cell enzyme and red membrane deficiencies

**Marianne E. Yee, M.D., M.Sc.:** Clinical research in sickle cell disease, hemoglobin disorders, transfusion therapy and BMT for patients with sickle cell disease

**Hemophilia/thrombosis**

**Glavy Batsui, M.D.:** Basic and translational research in hemophilia A and inhibitors

**Carolyn M. Bennett, M.D.:** Platelet disorders including immune thrombocytopenic purpura (ITP)

**Christine L. Kempton, M.D.:** Clinical trials in hemophilia with an emphasis on inhibitors

**Shannon L. Meeks, M.D.:** Basic and translational research in hemophilia A and inhibitors

**Kavita Patel, M.D.:** Thrombosis treatment and prevention

**Robert Sidonio Jr., M.D., Clinical Director of Hemostasis/Thrombosis:** von Willebrand disease, thrombosis treatment and prevention

**Katie Santilli, M.S.:** Translational research in sickle cell disease, hemoglobin disorders, transfusion therapy and BMT for patients with sickle cell disease

**Muna Qayed, M.D., M.S.C.R.:** Incorporation of novel agents into the treatment of relapsed solid tumors, improving current treatments for patients with high-risk disease including autologous stem cell transplant and developing more effective prophylaxis/treatment against GVHD in patients undergoing allogeneic BMT

**Elizabeth O. Stenger, M.D.:** BMT for nonmalignant disease, tolerance and GVHD prevention/treatment

**Benjamin Watkins, M.D.:** Clinical trials and research in developing more effective prophylaxis/treatment against GVHD in patients undergoing allogeneic BMT

### Sickle cell disease

**Olufolake Adisa, M.D.:** Translational research in sickle cell disease with primary focus on hemoglobinopathy and pulmonary complications of sickle cell disease

**R. Clark Brown, M.D., Ph.D.:** Targeted therapies for thalassemia and sickle cell disease

**Carlton D. Dampier, M.D.:** Clinical trials in sickle cell disease, measurement science of patient- and parent-reported outcomes and symptom management in sickle cell disease, particularly pain

**Anne G. James-Herry, M.D.:** Clinical trials in sickle cell disease, comprehensive sickle cell disease, and specialty clinics, particularly pulmonary and GI- and age-based clinics
Clinton H. Joiner, M.D., Ph.D., Director of Hematology: Red cell physiology, specifically cation transport and volume regulation and their perturbation in sickle cell disease

Peter A. Lane, M.D.: Newborn screening, health outcomes and clinical trials in sickle cell disease

Tamara N. Neve, M.D.: Clinical trials in sickle cell disease, interest in chronic pain, pulmonary complications and global impact of sickle cell in economically poor countries

Maa-Ohui Quaryme, M.B.Ch.B.: Sickle cell disease and thalassemias, stroke prevention in sickle cell disease and outcomes in sickle cell disease

Transfusion medicine
Cassandra D. Josephson, M.D.: Clinical transfusion medicine and blood safety in hemophilia, sickle cell disease, neonatology and open heart surgery

Oncology
Leukemia/lymphoma
D. John Bergsagel, M.D.: Clinical trials in leukemia and lymphoma

Sharon Castellino, M.D., Director of Leukemia and Lymphoma: Hodgkin lymphoma and survivorship

Frank G. Keller, M.D., Clinical Director of Leukemia: PI of COG trial for low-risk Hodgkin’s disease and clinical trials in Hodgkin’s disease, non-Hodgkin’s lymphoma (NHL) and leukemia

Glén Lew, M.D.: Study chair of COG Phase III trial for relapsed acute lymphoblastic leukemia (ALL); etiology, treatment and outcomes in childhood ALL

Katherine Minson, M.D.: Novel therapeutic targets in AML

Melinda Pauly, M.D.: Relationship of the BCL-2 family of proteins within the intrinsic apoptotic pathway to members of the autophagy pathway

Himalee Sabnis, M.D., M.S.: Biology of acute myeloid leukemia (AML), signaling pathways in leukemic cells and new therapeutic agents in AML

William G. Woods, M.D.: Clinical trials within COG in myeloid leukemia

Palliative care
Katharine Brock, M.D., M.S.: Clinical research in palliative care

Solid tumors
Thomas Cash, M.D., M.Sc.: Outcomes and epidemiology in rare pediatric tumors; the role of ezrin and tumor necrosis in patients with Ewing Sarcoma; innovative therapy and Phase II trials

Bradley A. George, M.D.: Solid tumors and histiocytosis

Kelly Goldsmith, M.D.: Basic and translational research of neuroblastoma, with a primary focus on mechanisms of therapy resistance

Thomas A. Olson, M.D., Clinical Director of Solid Tumors: Committee chair for COG germ cell disease, clinical trials in germ cell tumors, retinoblastoma and bone tumors

Louis B. Rapkin, M.D.: Rare tumors, clinical trials in solid tumors and the development of educational curriculum for house staff and fellows

Katie Sutton, M.D.: Clinical researcher in neuroblastoma and solid tumors

Karen Wasilewski-Masker, M.D., M.Sc.: Bone sarcomas; adolescent/young adult oncology; supportive care/cancer control studies; transition of care

Neuro-oncology
Dolly Aguilera, M.D.: Development of Phase I and Phase II clinical trials for children with recurrent brain tumors

Anna J. Janss, M.D., Ph.D.: Phase I clinical trials (COG) and innovative therapeutics for brain tumors

Tobey J. MacDonald, M.D., Director of Neuro-oncology: Basic and translational research of childhood brain tumors with a primary research focus on the metastasis and role of platelet-derived growth factor receptor (PDGF) signaling

Claire M. Mazewski, M.D.: PI of COG high-risk medulloblastoma trial for young children, clinical trials, innovative therapeutics and late effects studies for children with brain tumors

Cynthia Wetmore, M.D., Ph.D., Director of Developmental Therapeutics: Clinical research in developmental therapeutics for pediatric oncology and neuro-oncology; design and conduct of Phase I/II clinical studies; translation of basic science discoveries to improving clinical care of patients

Junior faculty
Nitya Bakshi, M.D.: Pain in sickle cell disease including psychophysical pain phenotyping in pediatric patients with sickle cell disease and development and validation of electronic pain diaries for children with sickle cell disease

Katie Metrock, M.D.: Neuro-oncology

Joanna Newton, M.D.: Racial and ethnic disparities in pediatric AML outcomes; expression of CD36 and the presence of cytoplasmic granules in blasts predicts poor prognosis in children with B-lymphoblastic leukemia

Sunil Raikar, M.D.: Development of novel chimeric antigen receptor (CAR) natural killer cells against T-cell malignancies

Psychology and neuropsychology
Grace Fong, Ph.D.: Acquired brain injury and clinical trials for late effects

Jordan Gilleland, Ph.D.: Childhood cancer survivorship and transition to adult care

Lisa Ingerski, Ph.D.: Child psychology

Alcuin Johnson, Ph.D.: Acquired brain injury; transition to adult care and motivational interviewing

Laura Mee, Ph.D.: Parent coping, parent training and quality of life

Soumitri Sil, Ph.D.: Acute and chronic pain management

Beth Thompson, Psy.D.: Pain management, pica and coping with chronic illness

Cancer survivorship
Lillian R. Meacham, M.D., Clinical Director of Survivorship: Childhood Cancer Survivor Study (CCSS), educating survivors and providers about survivor care, and endocrine late effects in oncology patients

Ann C. Mortens, Ph.D., Research Director of Survivorship: Childhood and adolescent cancer survivorship

Briana C. Patterson, M.D.: Late effects of cancer therapy in brain tumor patients and endocrine problems following cancer treatment

Karen Wasilewski-Masker, M.D., M.Sc.: Outcomes/cancer survivor research and transition of care
Lab research/developmental therapeutics

David R. Archer, Ph.D.: Hematopoietic stem cell transplant for genetic disease, particularly sickle cell disease and use of stem cells in regenerative medicine

Vaughn Barry, Ph.D.: Epidemiology outcomes research and epidemiologic methods; study design and analysis of blood disorders including sickle cell disease and hemophilia

Kevin D. Bunting, Ph.D., Research Director of Leukemia and Lymphoma: Studies of normal cytokine signaling in hematopoiesis and dysregulated signaling associated with inflammation and cancer

Robert C. Castellino, M.D.: Pediatric neuro-oncology; interactions between p53/Hedgehog/and PI-3 Kinase cell signaling in neuronal development, brain tumor development or progression, and as targets for drug development

Deborah DeRyckere, Ph.D.: Preclinical development of novel small molecule MerTK inhibitors for oncology applications, TAM-family receptor tyrosine signaling and biology, murine xenograft models of acute leukemia

Christopher B. Doering, Ph.D.: Development of modified blood coagulation factors and implementation in gene transfer-based therapies

Lubing Gu, M.D.: Molecular mechanisms of drug resistance in childhood cancer and leukemia

Delores Hambardzumyan, Ph.D.: Neuro-oncology

Curtis Henry, Ph.D.: Leukemia research

Anna M. Kenney, Ph.D.: How Sonic hedgehog and interacting signal transduction pathways control normal and neoplastic development within the cerebellum

Wilbur A. Lam, M.D., Ph.D.: Development and application of novel bioengineering technologies to study, diagnose and treat hematologic disorders

Renhao Li, Ph.D.: Development of novel reagents to improve bleeding diagnostics and platelet storage

Pete Lollar, M.D., Research Director of Hemostasis: Development of novel recombinant Factor VIII molecules for use in preventing and treating hemophilia patients with inhibitors and basic research in biosynthesis and expression of Factor VIII

Brian Petrich, Ph.D.: Regulation of platelet integrin signaling in hemostasis and thrombosis; cell adhesion mechanisms in vascular disease and thrombosis

Chris Porter, M.D.: Cancer genetics and leukemia research

Cheng-Kui Ou, M.D., Ph.D.: Cell signaling and metabolic regulation of hematopoietic stem cells focusing on the role of protein and lipid phosphatases in normal hematopoietic cell development and leukemogenesis; development of novel therapeutics for phosphatases-associated blood disorders, such as juvenile myelomonocytic leukemia

Robert Schnepp, M.D., Ph.D.: Neuroblastoma research

H. Trent Spencer, Ph.D., Director of Gene Therapy: Developing and implementing cell and gene therapy for the treatment of childhood cancer and inherited diseases, with a specific emphasis on the genetic engineering of hematopoietic stem cells

Zhengqi Wang, Ph.D.: Study of STAT5 and its function in signaling mechanisms in leukemogenesis, hematopoietic stem cell biology and transplant

Muxiang Zhou, M.D.: Signaling pathways and regulators of apoptosis relating to drug resistance in ALL

Atlanta

Ranked among the fastest-growing metropolitan areas in the country*, Atlanta combines Southern hospitality with the amenities of any world-class city. More than 5 million metro Atlanta residents enjoy the city’s rich history and cultural diversity. Whether you are a sports fanatic, history buff or have a love of the arts, metro Atlanta offers something for everyone.

World-class, modern city with a rich history

Why Atlanta?

• Cost of living is less expensive than other major cities**
• Hartsfield-Jackson Atlanta International Airport is the world’s busiest airport
• Atlanta is within a two-hour flight of 80 percent of the United States
• Home to more than 12 Fortune 500 companies and more than 15 Fortune 1000 companies
• Museums, theaters and eclectic shopping areas
• Professional sports teams, including the Falcons, Braves and Hawks
• Vast number of restaurant options, including a wealth of ethnic cuisines
• Seasonal climate suitable for outdoor activities nearly year-round
• Within driving distance to both the mountains and the ocean

*forbes.com
** metroatlantachamber.com
Visit aflaccancercenter.org for more information.

Email Angie Graves at angie.graves@emory.edu.
Email William Woods, M.D., at william.woods@choa.org.

All applications are accepted through ERAS. A requirements checklist is available online.